Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Retained Earnings (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Retained Earnings readings, the most recent being -$27.5 million for Q4 2017.

  • On a quarterly basis, Retained Earnings fell 91.15% to -$27.5 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$27.5 million, a 91.15% decrease, with the full-year FY2017 number at -$27.5 million, down 91.15% from a year prior.
  • Retained Earnings hit -$27.5 million in Q4 2017 for Eledon Pharmaceuticals, down from -$25.4 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $3000.0 in Q3 2016 to a low of -$173.3 million in Q1 2017.
  • Median Retained Earnings over the past 5 years was -$80.1 million (2014), compared with a mean of -$76.2 million.
  • The widest YoY moves for Retained Earnings: up 100.0% in 2016, down 7819400.0% in 2016.
  • Eledon Pharmaceuticals' Retained Earnings stood at -$63.1 million in 2013, then tumbled by 36.95% to -$86.4 million in 2014, then crashed by 52.21% to -$131.4 million in 2015, then surged by 89.05% to -$14.4 million in 2016, then tumbled by 91.15% to -$27.5 million in 2017.
  • The last three reported values for Retained Earnings were -$27.5 million (Q4 2017), -$25.4 million (Q3 2017), and -$22.4 million (Q2 2017) per Business Quant data.